Impact of Initial Therapy on Front Line Maintenance Treatment Choice in Advanced Ovarian Cancer

Video

An expert in ovarian cancer describes how initial first line therapy impacts first line maintenance options.

Recent Videos
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Treatment with mirvetuximab soravtansine appears to produce a 3-fold improvement in objective response rate vs chemotherapy among patients with folate receptor-α–expressing, platinum-resistant ovarian cancer in the phase 3 MIRASOL trial.
Related Content
Rucaparib Findings Highlight Need for More Data in BRCA+ Ovarian Carcinoma

Rucaparib Findings Highlight Need for More Data in BRCA+ Ovarian Carcinoma

Tim Cortese
February 23rd 2025
Article

Data show that rucaparib yielded a median OS of 19.4 months compared with 25.4 months with chemotherapy in relapsed BRCA-mutated ovarian carcinoma.

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

New AI Technology May Have the Potential to Optimize Cancer Surgery

New AI Technology May Have the Potential to Optimize Cancer Surgery

Tim Cortese
February 3rd 2025
Article

Anant Madabhushi, PhD, and Farzad Fereidouni, PhD, are developing the MarginCall technology to reduce time lag and improve tumor margin assessment accuracy in breast and ovarian cancer surgery.

Population Testing to Prevent Gynecologic Cancers

Population Testing to Prevent Gynecologic Cancers

Ranjit Manchanda, MD, PhD
September 12th 2018
Podcast

Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.

Avutometinib With Defactinib Accepted for Review by FDA in Recurrent LGSOC

Avutometinib With Defactinib Accepted for Review by FDA in Recurrent LGSOC

Tim Cortese
January 2nd 2025
Article

Avutometinib/defactinib was granted priority review by the FDA in the treatment of patients with recurrent, KRAS-mutant low-grade serous ovarian cancer.

Niraparib/Dostarlimab/Chemo Improves PFS Vs SOC in Advanced Ovarian Cancer

Niraparib/Dostarlimab/Chemo Improves PFS Vs SOC in Advanced Ovarian Cancer

Tim Cortese
December 20th 2024
Article

Niraparib/dostarlimab with platinum-therapy met its PFS end point in patients with advanced ovarian cancer in the phase 3 FIRST-ENGOT-OV44 trial.